Emerging Arylcyclohexylamines in Forensic Toxicology

Direct answer: emerging arylcyclohexylamines can present a difficult forensic-identification problem because closely related ketamine- and phencyclidine-type compounds may share nominal masses, precursor ions, product ions, or broadly similar fragmentation. A defensible identification therefore depends on the validated method, chromatographic behavior, reference material, spectral agreement, and—when structural isomers remain plausible—orthogonal analytical evidence rather than a single mass-spectral match.

Why arylcyclohexylamines are an emerging forensic problem

Arylcyclohexylamines include ketamine, phencyclidine (PCP), and a growing group of new psychoactive substances (NPS) designed around related structural scaffolds. New analogues may differ only by the position of a fluorine or methoxy substituent, the identity of an N-alkyl group, or another small structural modification. Those changes can be enough to create a legally distinct substance while leaving much of the analytical behavior similar.

A September 4, 2026 Forensic Science International study by Yeon and colleagues systematically characterized nine emerging arylcyclohexylamines using nuclear magnetic resonance (NMR), GC-MS, LC-QTOF-MS, and LC-MS/MS. The compounds included three positional fluoro-2-oxo-PCM isomers, several N-alkyl analogues, 2-oxo-PCPr, 2-oxo-PCP, and 3-MeO-2-oxo-PCP. The central analytical lesson is important for forensic casework: structurally similar arylcyclohexylamines may require multiple complementary techniques for reliable differentiation.

Why a single precursor ion may not establish identity

Mass spectrometry is highly selective, but selectivity is not absolute. Closely related compounds may generate the same nominal precursor mass, similar high-resolution exact masses, or overlapping product ions. Positional isomers are especially challenging because they have the same elemental composition and therefore the same exact molecular mass.

For a case review, the question is not simply whether an instrument produced a peak at the expected mass-to-charge ratio. The more probative questions are whether the laboratory demonstrated adequate chromatographic separation, whether the retention time matched an appropriate reference standard, whether the required identification ions or ion ratios met validated criteria, and whether known or reasonably foreseeable isomers were evaluated.

What the major analytical techniques contribute

Technique	Primary forensic value	Important limitation
LC-MS/MS	Sensitive routine screening and confirmation; reproducible targeted transitions	Structurally related analogues may share transitions or similar fragmentation
LC-QTOF-MS / HRMS	Accurate mass, full-scan data, product-ion spectra, retrospective data review	Exact mass alone cannot distinguish positional isomers
GC-MS	Electron-ionization fragmentation and chromatographic behavior can provide useful distinguishing features	Library coverage may lag behind newly emerging NPS
NMR	Powerful structural elucidation and positional-isomer differentiation	Generally requires more material and is not a routine toxicology confirmation tool for low-level biological specimens

Positional isomers are the key identification challenge

The 2026 Yeon study examined 2-fluoro-, 3-fluoro-, and 4-fluoro-2-oxo-PCM. These compounds share the same elemental composition but differ in where fluorine is located on the aromatic ring. NMR provided unambiguous structural information, while GC-MS fragmentation and relative fragment intensities also helped distinguish the isomers. LC-QTOF-MS supplied accurate-mass and product-ion information, and LC-MS/MS produced reproducible fragmentation suitable for routine forensic screening.

The practical point is that a laboratory should not assume that a transition is unique merely because it is sensitive. Where positional isomers or homologues are reasonably plausible, the method should demonstrate how the reported compound is distinguished from those alternatives.

Reference standards and retention time matter

For targeted confirmation, comparison to a certified or otherwise appropriately characterized reference material is often central to identification. A reference standard can support retention-time matching and expected response behavior under the laboratory’s own conditions. A database spectrum obtained elsewhere may be useful, but it is not equivalent to demonstrating that the laboratory’s method resolves the analyte from relevant interferents and isomers.

When reviewing a positive result, determine whether the exact analogue was included in validation and whether the laboratory had a reference standard for that analogue at the time of analysis. A broad library match to a chemical family should not automatically be treated as compound-specific identification.

Library-search limitations for newly emerging NPS

Emerging drugs can appear in seized material or biological specimens before commercial libraries and routine targeted panels are updated. This creates two distinct risks. First, a novel compound may be missed because it is absent from the target list. Second, an unknown may be assigned to a close structural relative because the library contains only the older analogue.

High-resolution full-scan data can improve retrospective review because a laboratory may later re-interrogate stored data for newly recognized compounds. But retrospective detection still requires appropriate identification criteria and, where necessary, confirmatory analysis or reference material.

Biological specimen testing is different from seized-drug characterization

NMR and comprehensive structural characterization may be practical for a relatively pure seized material but not for a low-concentration analyte in blood or urine. In biological toxicology, the defensibility of identification often depends more heavily on validated chromatographic separation, LC-MS/MS or HRMS criteria, reference standards, matrix-specific performance, and metabolite evidence.

That distinction matters when literature generated from neat reference material is used to support a biological-specimen conclusion. A spectrum can show that two compounds are analytically distinguishable in principle without proving that a specific toxicology method separates them at relevant concentrations in a complex matrix.

Metabolites can provide additional context

Where metabolism is known, detection of a parent compound together with plausible metabolites can add interpretive support. However, metabolites may themselves be shared across analogues or may not yet be well characterized for a newly emerging substance. Metabolite evidence should therefore be evaluated as part of the total analytical picture rather than treated as an automatic substitute for parent-drug specificity.

Forensic case-review checklist

What exact arylcyclohexylamine was reported?
Was the compound included in the laboratory’s validated scope at the time of testing?
Was an authentic reference standard analyzed?
What chromatographic retention-time tolerance was required?
Which precursor/product ions or exact-mass criteria were used?
Were ion-ratio or qualifier-ion criteria satisfied?
Could positional isomers or homologues produce the same monitored transitions?
Did validation test those potential interferents?
Was chromatographic separation demonstrated?
Was the identification based on targeted LC-MS/MS, HRMS library searching, GC-MS, or a combination?
If a library was used, did it contain the relevant isomers and was the version current at the time?
Were full-scan data retained for retrospective review?
Were parent drug and metabolites both detected, and are those metabolites specific?
Is the conclusion compound-specific, or is only a chemical class supported?

What a defensible conclusion should say

The strength of an arylcyclohexylamine identification should track the specificity of the underlying data. If a validated targeted method resolves the analyte from relevant isomers, uses an appropriate standard, and satisfies confirmation criteria, a compound-specific conclusion may be warranted. If the method cannot distinguish plausible structural alternatives, the scientifically supportable conclusion may need to be narrower—for example, identification of an arylcyclohexylamine consistent with a particular analogue rather than an unequivocal assignment.

This distinction is particularly important in criminal, impaired-driving, and death-investigation cases in which the identity of a specific analogue can affect scheduling, charging, toxicological interpretation, or the weight assigned to the result.

Related technical resources

Primary sources

Yeon S, Park J, Cho B, et al. Emerging arylcyclohexylamine new psychoactive substances: comprehensive characterization and differentiation by NMR, GC-MS, LC-QTOF-MS and LC-MS/MS. Forensic Science International. 2026;389:113122. DOI: 10.1016/j.forsciint.2026.113122. PubMed: PMID 42731371.

Wallach J, et al. Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines. Drug Testing and Analysis. DOI: 10.1002/dta.1861.

Technical review: Forensic Toxicology Working Group Members. This page is educational and addresses analytical interpretation; it is not a substitute for review of the laboratory’s complete case file, validation records, and raw data.

Emerging Arylcyclohexylamines in Forensic Toxicology: Analytical Differentiation of Ketamine-Like NPS